Revenue Recognition (Tables)

12 Months Ended

Dec. 31, 2021

Revenue from Contract with Customer [Abstract]

Disaggregation of Revenue

Segment information for each of the fiscal years are as follows (in thousands):

	Year Ended December 31, 2021
	Performance Enzymes		Novel Biotherapeutics		Total
Major products and service:
Product revenue	$	70,657	$	—	$	70,657
Research and development revenue	19,858		14,239		34,097
Total revenues	$	90,515	$	14,239	$	104,754
Primary geographical markets:
Americas	$	16,114	$	7,367	$	23,481
EMEA	13,315		6,872		20,187
APAC	61,086		—		61,086
Total revenues	$	90,515	$	14,239	$	104,754

	Year Ended December 31, 2020
	Performance Enzymes		Novel Biotherapeutics		Total
Major products and service:
Product revenue	$	30,220	$	—	$	30,220
Research and development revenue	17,886		20,950		38,836
Total revenues	$	48,106	$	20,950	$	69,056
Primary geographical markets:
Americas	$	11,111	$	13,241	$	24,352
EMEA	11,548		7,709		19,257
APAC	25,447		—		25,447
Total revenues	$	48,106	$	20,950	$	69,056

	Year Ended December 31, 2019
	Performance Enzymes		Novel Biotherapeutics		Total
Major products and service:
Product revenue	$	29,465	$	—	$	29,465
Research and development revenue	28,691		10,302		38,993
Total revenues	$	58,156	$	10,302	$	68,458
Primary geographical markets:
Americas	$	13,039	$	—	$	13,039
EMEA	26,831		10,302		37,133
APAC	18,286		—		18,286
Total revenues	$	58,156	$	10,302	$	68,458

Contract Balances

The following table presents balances of contract assets, unbilled receivables, contract costs, and contract liabilities (in thousands):

	December 31, 2021		December 31, 2020
Contract assets	$	4,557	$	4,526
Unbilled receivables	$	8,558	$	10,942
Contract costs	$	56	$	90
Contract liabilities: deferred revenue	$	6,335	$	4,791

Contract with Customer

We recognized the following revenues (in thousands):

	Year Ended December 31,
Revenue recognized in the period for:	2021		2020
Amounts included in contract liabilities at the beginning of the period:
Performance obligations satisfied	$	1,858	$	57
Changes in the period:
Changes in the estimated transaction price allocated to performance obligations satisfied in prior periods	7,645		774
Performance obligations satisfied from new activities in the period - contract revenue	95,251		68,225
Total revenues	$	104,754	$	69,056

Performance Obligation, Expected Timing of Satisfaction

The balances in the table below are partially based on judgments involved in estimating future orders from customers subject to the exercise of material rights pursuant to respective contracts (in thousands):

	2022		2023		2024		2025 and Thereafter		Total
Product revenue	$	89	$	87	$	120	$	2,985	$	3,281
Research and development revenue	2,497		557		—		—		3,054
Total revenues	$	2,586	$	644	$	120	$	2,985	$	6,335